Nov 21, 2022 Cellectar Biosciences Announces Presentation of Data on CLR 12120 Series of Targeted Alpha-Emitting Therapies at the 13th Annual World ADC Conference Learn More
Nov 16, 2022 Cellectar Announces Resolution of Breach of Contract and Intellectual Property Dispute Learn More
Nov 3, 2022 Cellectar Reports Financial Results for Third Quarter 2022 and Provides a Corporate Update Learn More
Oct 25, 2022 Cellectar Biosciences Announces Closing of Concurrent Registered Direct and Private Placement Offerings of Approximately $10.7 Million Priced At-The-Market Under Nasdaq Rules Learn More